Repository logo
 
Publication

Use of albumin infusion for cirrhosis-related complications: An international position statement

2023-05Journal article Open access
Simple item page
dc.contributor.authorBai, Zhaohui
dc.contributor.authorMéndez-Sánchez, Nahum
dc.contributor.authorRomeiro, Fernando Gomes
dc.contributor.authorMancuso, Andrea
dc.contributor.authorPhilips, Cyriac Abby
dc.contributor.authorTacke, Frank
dc.contributor.authorBasaranoglu, Metin
dc.contributor.authorPrimignani, Massimo
dc.contributor.authorIbrahim, Mostafa
dc.contributor.authorWong, Yu Jun
dc.contributor.authorNery, Filipe Gaio
dc.contributor.authorTeschke, Rolf
dc.contributor.authorFerreira, Carlos Noronha
dc.contributor.authorMuñoz, Alberto E.
dc.contributor.authorPinyopornpanish, Kanokwan
dc.contributor.authorThevenot, Thierry
dc.contributor.authorSingh, Shivaram Prasad
dc.contributor.authorMohanty, Arpan
dc.contributor.authorSatapathy, Sanjaya K.
dc.contributor.authorRidola, Lorenzo
dc.contributor.authorMaruyama, Hitoshi
dc.contributor.authorCholongitas, Evangelos
dc.contributor.authorLevi Sandri, Giovanni Battista
dc.contributor.authorYang, Li
dc.contributor.authorShalimar, null
dc.contributor.authorYang, Yongping
dc.contributor.authorVilla, Erica
dc.contributor.authorKrag, Aleksander
dc.contributor.authorWong, Florence
dc.contributor.authorJalan, Rajiv
dc.contributor.authorO’Brien, Alastair
dc.contributor.authorBernardi, Mauro
dc.contributor.authorQi, Xingshun
dc.date.accessioned2024-07-04T14:18:06Z
dc.date.available2024-07-04T14:18:06Z
dc.date.issued2023-05
dc.description.abstractBackground & aims: Numerous studies have evaluated the role of human albumin (HA) in managing various liver cirrhosis-related complications. However, their conclusions remain partially controversial, probably because HA was evaluated in different settings, including indications, patient characteristics, and dosage and duration of therapy. Methods: Thirty-three investigators from 19 countries with expertise in the management of liver cirrhosis-related complications were invited to organise an International Special Interest Group. A three-round Delphi consensus process was conducted to complete the international position statement on the use of HA for treatment of liver cirrhosis-related complications. Results: Twelve clinically significant position statements were proposed. Short-term infusion of HA should be recommended for the management of hepatorenal syndrome, large volume paracentesis, and spontaneous bacterial peritonitis in liver cirrhosis. Its effects on the prevention or treatment of other liver cirrhosis-related complications should be further elucidated. Long-term HA administration can be considered in specific settings. Pulmonary oedema should be closely monitored as a potential adverse effect in cirrhotic patients receiving HA infusion. Conclusions: Based on the currently available evidence, the international position statement suggests the potential benefits of HA for the management of multiple liver cirrhosis-related complications and summarises its safety profile. However, its optimal timing and infusion strategy remain to be further elucidated.Impact and implications: Thirty-three investigators from 19 countries proposed 12 position statements on the use of human albumin (HA) infusion in liver cirrhosis-related complications. Based on current evidence, short-term HA infusion should be recommended for the management of HRS, LVP, and SBP; whereas, long-term HA administration can be considered in the setting where budget and logistical issues can be resolved. However, pulmonary oedema should be closely monitored in cirrhotic patients who receive HA infusion.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBai Z, Méndez-Sánchez N, Romeiro FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023;5(8):100785. doi:10.1016/j.jhepr.2023.100785pt_PT
dc.identifier.doi10.1016/j.jhepr.2023.100785pt_PT
dc.identifier.issn2589-5559
dc.identifier.urihttp://hdl.handle.net/10400.16/3003
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevier B.Vpt_PT
dc.relation.publisherversionhttps://doi.org/10.1016/j.jhepr.2023.100785pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectDecompensatedpt_PT
dc.subjectHuman albuminpt_PT
dc.subjectKidney injurypt_PT
dc.subjectLiver failurept_PT
dc.subjectManagementpt_PT
dc.subjectPortal hypertensionpt_PT
dc.subjectSepsispt_PT
dc.titleUse of albumin infusion for cirrhosis-related complications: An international position statementpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceNetherlandspt_PT
oaire.citation.issue8pt_PT
oaire.citation.startPage100785pt_PT
oaire.citation.titleJHEP Reportspt_PT
oaire.citation.volume5pt_PT
person.familyNameNery
person.givenNameFilipe
person.identifier.orcid0000-0001-6644-2985
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication781a1e97-0947-4a26-8f9a-611d6c0e97fa
relation.isAuthorOfPublication.latestForDiscovery781a1e97-0947-4a26-8f9a-611d6c0e97fa

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bai-2023-Use-of-albumin-infusion-for-cirrhos.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SCI1- Artigos publicados em revistas indexadas na Pubmed/Medline